Hormone Replacement Therapy in the context of Transgender Care, often called Gender-Affirming Hormone Therapy (GAHT), is highly specialized and goal-oriented. The primary objective is to align a person's secondary sexual characteristics with their gender identity, which significantly improves psychological well-being and reduces gender dysphoria. This involves two main approaches: masculinizing therapy (testosterone, often injectable or gel) for trans men, and feminizing therapy (estrogen, often combined with anti-androgens like Spironolactone) for trans women.

Unlike menopausal HRT, these regimens aim to induce a "second puberty," causing sustained physical changes like body fat redistribution, muscle mass change, and hair growth/loss patterns. A key clinical consideration is risk management; feminizing therapy carries an increased risk of venous thromboembolism (VTE), especially with oral estrogen, necessitating careful patient monitoring and risk stratification (e.g., discouraging smoking). Ongoing preventative care, including cancer screenings appropriate to existing organs (e.g., mammograms for trans women on estrogen), remains essential.

Related Reports